- Home
- ILAG vs AFMD Comparison
ILAG vs AFMD Comparison
Compare ILAG & AFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- AFMD
- Stock Information
- Founded
- ILAG 1981
- AFMD 2000
- Country
- ILAG Hong Kong
- AFMD Germany
- Employees
- ILAG N/A
- AFMD N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- AFMD Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- AFMD Health Care
- Exchange
- ILAG Nasdaq
- AFMD Nasdaq
- Market Cap
- ILAG 15.9M
- AFMD 17.5M
- IPO Year
- ILAG 2022
- AFMD 2014
- Fundamental
- Price
- ILAG $0.86
- AFMD $1.15
- Analyst Decision
- ILAG
- AFMD Strong Buy
- Analyst Count
- ILAG 0
- AFMD 5
- Target Price
- ILAG N/A
- AFMD $13.50
- AVG Volume (30 Days)
- ILAG 39.9K
- AFMD 363.4K
- Earning Date
- ILAG 12-20-2024
- AFMD 11-14-2024
- Dividend Yield
- ILAG N/A
- AFMD N/A
- EPS Growth
- ILAG N/A
- AFMD N/A
- EPS
- ILAG N/A
- AFMD N/A
- Revenue
- ILAG $8,980,747.00
- AFMD $6,287,085.00
- Revenue This Year
- ILAG N/A
- AFMD N/A
- Revenue Next Year
- ILAG N/A
- AFMD $212.48
- P/E Ratio
- ILAG N/A
- AFMD N/A
- Revenue Growth
- ILAG 33.03
- AFMD N/A
- 52 Week Low
- ILAG $0.33
- AFMD $1.03
- 52 Week High
- ILAG $1.35
- AFMD $8.95
- Technical
- Relative Strength Index (RSI)
- ILAG 44.31
- AFMD 28.57
- Support Level
- ILAG $0.84
- AFMD $1.03
- Resistance Level
- ILAG $0.92
- AFMD $1.41
- Average True Range (ATR)
- ILAG 0.06
- AFMD 0.11
- MACD
- ILAG 0.00
- AFMD 0.05
- Stochastic Oscillator
- ILAG 27.56
- AFMD 23.53
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc is engaged in the business of manufacturing and selling mechanical locksets. The business is spread across the Unites States, Canada, Australia, and China. Majority of the revenue is generated from the United States.
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.